Target Price | €150.45 |
Price | €112.20 |
Potential | 34.09% |
Number of Estimates | 20 |
20 Analysts have issued a price target Merck 2026 . The average Merck target price is €150.45. This is 34.09% higher than the current stock price. The highest price target is €197.40 75.94% , the lowest is €101.00 9.98% . | |
A rating was issued by 24 analysts: 17 Analysts recommend Merck to buy, 4 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 34.09% . Most analysts recommend the Merck stock at Purchase. |
20 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €21.4b . This is 1.06% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €23.4b 10.23% , the lowest is €20.5b 3.57% .
This results in the following potential growth metrics:
2024 | €21.2b | 0.78% |
---|---|---|
2025 | €21.4b | 1.36% |
2026 | €22.2b | 3.58% |
2027 | €23.0b | 3.67% |
2028 | €24.0b | 4.33% |
2029 | €25.2b | 4.70% |
2030 | €25.8b | 2.72% |
2031 | €25.3b | 2.16% |
2032 | €26.0b | 2.71% |
19 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.1b . This is 6.69% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €7.2b 25.26% , the lowest is €5.6b 2.01% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €4.9b | 3.42% |
---|---|---|
2025 | €6.1b | 24.60% |
2026 | €6.4b | 4.79% |
2027 | €6.8b | 4.88% |
2028 | €7.1b | 4.72% |
2029 | €7.5b | 6.58% |
2030 | €7.8b | 3.48% |
2031 | €8.0b | 1.99% |
2032 | €8.1b | 2.16% |
2024 | 23.31% | 2.62% |
---|---|---|
2025 | 28.65% | 22.92% |
2026 | 28.99% | 1.19% |
2027 | 29.32% | 1.14% |
2028 | 29.43% | 0.38% |
2029 | 29.96% | 1.80% |
2030 | 30.18% | 0.73% |
2031 | 31.46% | 4.24% |
2032 | 31.29% | 0.54% |
20 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.7b . This is 29.26% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €4.6b 59.51% , the lowest is €3.4b 18.95% .
This results in the following potential growth metrics and future Net Margins:
2024 | €2.8b | 1.66% |
---|---|---|
2025 | €3.7b | 33.22% |
2026 | €4.0b | 6.95% |
2027 | €4.2b | 5.91% |
2028 | €4.5b | 7.93% |
2029 | €4.9b | 8.56% |
2030 | €5.1b | 3.69% |
2031 | €5.3b | 4.69% |
2032 | €5.4b | 2.04% |
2024 | 13.13% | 2.42% |
---|---|---|
2025 | 17.25% | 31.42% |
2026 | 17.82% | 3.30% |
2027 | 18.20% | 2.13% |
2028 | 18.83% | 3.46% |
2029 | 19.52% | 3.66% |
2030 | 19.71% | 0.97% |
2031 | 21.09% | 7.00% |
2032 | 20.95% | 0.66% |
20 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €8.51 . This is 29.33% higher than earnings per share in the financial year 2024. The highest EPS forecast is €10.50 59.57% , the lowest is €7.83 19.00% .
This results in the following potential growth metrics and future valuations:
2024 | €6.39 | 1.69% |
---|---|---|
2025 | €8.51 | 33.18% |
2026 | €9.10 | 6.93% |
2027 | €9.64 | 5.93% |
2028 | €10.40 | 7.88% |
2029 | €11.29 | 8.56% |
2030 | €11.71 | 3.72% |
2031 | €12.26 | 4.70% |
2032 | €12.51 | 2.04% |
Current | 17.05 | 32.53% |
---|---|---|
2025 | 13.19 | 22.65% |
2026 | 12.33 | 6.52% |
2027 | 11.64 | 5.60% |
2028 | 10.79 | 7.30% |
2029 | 9.94 | 7.88% |
2030 | 9.58 | 3.62% |
2031 | 9.15 | 4.49% |
2032 | 8.97 | 1.97% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.63 and an P/S ratio of 2.27 .
This results in the following potential growth metrics and future valuations:
Current | 2.66 | 26.32% |
---|---|---|
2025 | 2.63 | 1.08% |
2026 | 2.54 | 3.45% |
2027 | 2.45 | 3.55% |
2028 | 2.35 | 4.15% |
2029 | 2.24 | 4.48% |
2030 | 2.18 | 2.65% |
2031 | 2.23 | 2.21% |
2032 | 2.17 | 2.64% |
Current | 2.29 | 29.60% |
---|---|---|
2025 | 2.27 | 1.04% |
2026 | 2.19 | 3.45% |
2027 | 2.11 | 3.54% |
2028 | 2.02 | 4.15% |
2029 | 1.93 | 4.49% |
2030 | 1.88 | 2.65% |
2031 | 1.92 | 2.21% |
2032 | 1.87 | 2.65% |
Analyst | Rating | Action | Date |
---|---|---|---|
EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Aug 29 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Buy
➜
Buy
|
Unchanged | Aug 29 2025 |
HSBC GLOBAL INVESTMENT RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 25 2025 |
STIFEL EUROPE |
Buy
➜
Sell
|
Downgrade | Aug 15 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Aug 13 2025 |
ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Aug 12 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Aug 11 2025 |
Analyst Rating | Date |
---|---|
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Aug 29 2025 |
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
|
Aug 29 2025 |
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
➜
Buy
|
Aug 25 2025 |
Downgrade
STIFEL EUROPE:
Buy
➜
Sell
|
Aug 15 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Aug 13 2025 |
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Aug 12 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Aug 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.